Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Figure 2

Effect of treatment on median progression-free survival (PFS) in all groups and subgroups. HR: hazard ratios; 95% CI: 95% confidence intervals.